Allergan To Pay $300M To End Birth Control Antitrust Case

Law360 (January 6, 2020, 5:26 PM EST) -- Allergan said on Monday that it has agreed to pay several groups of Loestrin buyers a total of $300 million and will avoid a looming trial over claims that a pair of its subsidiaries delayed generic alternatives to the birth control drug.

A trial was set to commence in Rhode Island federal court on Monday over claims that Warner Chilcott and Watson Pharmaceuticals violated antitrust law through patent settlements and other conduct that allegedly kept competing generic versions of Loestrin off the market.

Allergan said in a statement that the settlement includes no admission of wrongdoing and covers classes of direct...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!